James E. Bradner serves as the Executive Vice President of Research and Development at Amgen Inc., a leading biotechnology company. Before joining Amgen in 2023, Dr. Bradner had a distinguished career in both academia and the pharmaceutical industry. He earned his M.D. from Columbia University and completed his residency in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute. His academic journey also includes a notable tenure at Harvard Medical School, where he was a Professor of Medicine and led the Department of Medical Oncology at the Dana-Farber Cancer Institute. Dr. Bradner's contributions to the field of oncology are significant and widely recognized. He is best known for his pioneering work in chemical biology and the development of novel cancer therapies. One of his most notable achievements is the discovery of JQ1, a small molecule inhibitor that targets the BET family of proteins and has shown promise in treating various types of cancer. His research has been published in high-impact journals such as Nature and Cell, and he has received numerous awards, including the American Cancer Society Research Professorship and the Damon Runyon-Rachleff Innovation Award. In his current role at Amgen, Dr. Bradner oversees the company's global research and development efforts, focusing on advancing Amgen's pipeline of innovative medicines. His leadership is pivotal in driving the company's mission to transform the treatment of serious illnesses, particularly in oncology and other therapeutic areas. Under his guidance, Amgen continues to invest in cutting-edge science and technology to bring new therapies to patients worldwide. Dr. Bradner's strategic vision and commitment to scientific excellence are key assets in Amgen's ongoing pursuit of groundbreaking medical solutions.